Drugs / LB-DTK-MV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07670468 | Dec 2025 → Jun 2027 expected | Epstein-Barr virus infection, cytomegalovirus infection, polyomavirus infectious disease | LucasBio | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07685457 | Feb 2026 → May 2027 expected | Epstein-Barr virus infection, cytomegalovirus infection, polyomavirus infectious disease | LucasBio | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB-DTK-MV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07685457 ↗ |
| Modality | Cell therapy | “LB-DTK-MV is an allogeneic cell therapy product derived from a third-party donor” NCT07670468 ↗ |
| Route | Intravenous | “single intravenous infusion of LB-DTK-MV” NCT07670468 ↗ |